On the same date, Julian Gill also requested case numbers for all adverse events in the FAERS system related to tirzepatide and semaglutide products produced by Empower Pharmacy in Houston, Texas (both the 503A and 503B products). Noa Metta submitted on September 24 a request for FDA Form 483 inspection reports, warning letters, Establishment Inspection Reports, and adverse event reports relating to pharmacies conducting unauthorized compounding practices, involving semaglutide, tirzepatide, or similar drugs, between January 1, 2022, and the present. Several additional requests addressed non-compounding issues related to GLP-1 drugs, two mentioning Eli Lilly and one mentioning Ozempic and Wegovy
observed a correlation between high CHAC2 levels and mutant TP53, potentially due to hypomethylation of the CHAC2 promoter
Some physicians combine these approaches for patients who benefit from both appetite control and enhanced fat metabolism, though close medical monitoring is essential
GLP-1GLP-1 4
BDNF/NGF Pathway Enhancers (Lions Mane, 7,8-DHF) Mechanism: These aim to upregulate neurotrophins or mimic TrkB signaling, nudging plasticity
)
